Non-thromboembolic pulmonary hypertension in multiple myeloma, after thalidomide treatment: A pilot study
- 13 May 2008
- journal article
- research article
- Published by Elsevier BV in Annals of Oncology
- Vol. 19 (10), 1765-1769
- https://doi.org/10.1093/annonc/mdn287
Abstract
Background: Multiple myeloma (MM) is thrombogenic as a consequence of multiple hemostatic effects and endothelial damage. Thalidomide has been associated with an increased risk of thromboembolic pulmonary hypertension (PH). PH in the absence of venous thromboembolism has also been described in MM patients during thalidomide treatment. Aim: Detection of clinical and subclinical nonthromboembolic PH in MM patients after thalidomide treatment. Patients and methods: Eighty-two patients, 46–82 years (median age 61 years), 42 males, were studied. They underwent echocardiographic study at baseline, 1 month thereafter, 6 months later and whenever symptoms indicating deterioration of cardiac function appeared. Echocardiographic signs of PH were especially identified. Results: Clinical and echocardiographic evaluation revealed four patients (out of 82 patients, 4.87%) with PH. Nonimaging and imaging diagnostic methods excluded thromboembolic PH. Statistical analysis demonstrated significant correlation between structural heart disease and PH (r = 14.078; P = 0.008). No significant correlation between age (r = 0.770; P = 0.724), gender (r = 1.157; P = 0.285), International Staging System (ISS) (r = 0.316; P = 0.716) and PH was found. Conclusions: Preexisted endothelial dysfunction due to structural cardiac disease enhances the vasoactive substances release causing increased pulmonary vascular resistance. Thalidomide possibly causes a vasodilator and vasoconstriction imbalance, which may cause abnormal pulmonary vascular response interfering to a vicious circle perpetuating PH.This publication has 41 references indexed in Scilit:
- Can thalidomide improve outcome in patients with multiple myeloma?Nature Clinical Practice Oncology, 2006
- Mediators and modulators of pulmonary arterial hypertensionAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2006
- Thalidomide and lenalidomide in the treatment of multiple myelomaEuropean Journal of Cancer, 2006
- Phase III Clinical Trial of Thalidomide Plus Dexamethasone Compared With Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical Trial Coordinated by the Eastern Cooperative Oncology GroupJournal of Clinical Oncology, 2006
- Pulmonary vascular iNOS induction participates in the onset of chronic hypoxic pulmonary hypertensionAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2006
- Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinationsThrombosis and Haemostasis, 2006
- The endothelin system and its role in pulmonary arterial hypertension (PAH)Thorax, 2005
- Thalidomide Alone or With Dexamethasone for Previously Untreated Multiple MyelomaJournal of Clinical Oncology, 2003
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaThe New England Journal of Medicine, 1999
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences of the United States of America, 1994